Calendario de eventos




Advances in Genomics and Personalized Cancer Immunotherapy

Cancer treatment has historically taken a "one size fits all” approach. However, as scientists have learned more the role of genetic mutations in cancer, more personalized approaches have become possible. 

In this webinar for patients and caregivers, Robert D. Schreiber, PhD, of Washington University School of Medicine in St. Louis discusses how advances in our understanding of genomics have enabled doctors to identify the mutations driving individual tumors as well as how these tools are being utilized to develop personalized immunotherapy strategies for patients with a variety of cancers

Robert D. Schreiber, PhD, is the director of the Center for Human Immunology and Immunotherapy Programs, the co-leader of the Tumor Immunology Program of the Siteman Cancer Center, and the Andrew M. and Jane M. Bursky Distinguished Professor of Pathology & Immunology at the Washington University School of Medicine in St. Louis. Dr. Schreiber’s career has spanned the entire spectrum from laboratory research—where he has made monumental contributions to our fundamental understanding of adaptive immunity and cancer immunology—all the way to the clinic, where he is now focused on improving the effectiveness of personalized, patient-specific vaccine approaches against cancer. These clinical efforts are currently being explored in several clinical trials currently underway as well as several more that are planned.

The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, Genentech, Regeneron, and Advaxis. 

Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series.

Leer más:

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.